Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 03, 2019
Favorable Ruling in Second Patent Infringement Lawsuit Relating to Chugai’s Hemlibra
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (1st Section of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Tatsuro Kosaka |
| Inquiries to: | Masahiko Uchida, |
| General Manager, Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0881 |
TOKYO, October 3, 2019 -- Chugai Pharmaceutical Co., Ltd. announces today that a ruling in favor of Chugai has been rendered in the second lawsuit relating to Chugai’s Hemlibra® at the Intellectual Property High Court as follows.
- History
Service of Complaint May 10, 2018 Judgement October 3, 2019 - Reasons and Background of the Action
In the original trial, it was alleged by Baxalta that Chugai’s Hemlibra (generic name: emicizumab) for treatment of hemophilia A, infringed Baxalta’s patent (patent number 4313531) and thus it filed for an injunction in April 2016 against manufacture, usage, transfer, exportation, and offer of any transfer regarding Hemlibra, and disposal of stock. With regard to this action, the Tokyo District Court rendered a decision in favor of Chugai’s claim in March 2018. Given this ruling, Baxalta appealed to the Intellectual Property High Court and a decision in favor of Chugai’s claim was rendered by the High Court. - Party Who Filed the Appeal
(1) Name: Baxalta Incorporated
Baxalta GmbH(2) Address: 1200 Lakeside Drive Bannockburn, IL 60015, USA
Zählerweg 4, 6300 Zug, Switzerland - Contents of the Ruling
(1) Appeal shall be dismissed. (2) Court costs shall be borne by Baxalta. - Prospects
No changes are expected in Chugai’s financial prospects.
Trademarks used or mentioned in this release are protected by law.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
